Celonic AG, the Swiss biologics contract development and manufacturing organization, has appointed Soenke Brunswieck as Vice President Cell & Gene Therapy to establish Celonic`s new portfolio of CDMO Services in Cell & Gene Therapy domain.
“Cell & Gene Therapy represents a new paradigm in human health, with the potential to resolve unmet medical needs to improve patients’ lives through effective and safe advanced therapeutic medicinal products (ATMPs)”, said Dr. Konstantin Matentzoglu, CEO at Celonic AG. “Celonic appointed Soenke specifically for his extensive expertise with platform technologies and manufacturing of Cell & Gene Therapy Products”, added Dr. Matentzoglu.
Soenke is on-boarded by Celonic based on his excellent track record as Director of Business Development and Project Management at PharmaCell BV (now Lonza Netherlands BV), one of the leading CDMOs for Cell & Gene Therapies, based in the Netherlands. Prior to PharmaCell, Soenke was the Director of Marketing & Sales at CellGenix for over 10 years and was responsible for the creation and successful growth of the global market for GMP-reagents used in Cell and Gene Therapy.
Soenke Brunswieck, VP of Cell & Gene Therapy at Celonic added: „Celonic, as a premium quality-driven bio-pharmaceutical CDMO, now entering into the Cell & Gene Therapy services space, is taking a key strategic step to continue adding value to the fast-growing industry by developing and commercializing Cell Therapy & Gene Therapy Products“.
